Reports Q2 revenue $9.2B, consensus $8.91B. “We’re delivering strong performance and reaching more patients with innovative medicines and biosimilars that address serious diseases. We continue to invest in science that enables longer, healthier lives and supports sustainable, long-term growth,” said Robert Bradway, chairman and chief executive officer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Notable companies reporting after market close
- Is AMGN a Buy, Before Earnings?
- Amgen’s Promising Phase 3 Study on Weight Loss Drug Maridebart Cafraglutide
- Amgen’s Tarlatamab Study: A Potential Game-Changer in Lung Cancer Treatment
- Amgen’s AMG 193 Study: A Potential Game-Changer in Thoracic Tumor Treatment